Ra Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ra Pharmaceuticals, Inc.
Successful Phase III data for UCB’s C5 inhibitor zilucoplan adds to a similarly positive Phase III readout for its rozanolixizumab in December, but details are lacking. UCB is the only company with two mechanisms for MG.
Argenx's efgartigimod could very soon become the first anti-FcRn agent to get approval for generalized myasthenia gravis but UCB’s rival therapy rozanolixizumab for the rare muscular disease is nearly ready to be filed with regulators.
MK-0616 – administered orally – reduced LDL cholesterol in patients in two early clinical trials presented at the American Heart Association Scientific Sessions.
Private Company Edition: Recent biopharma venture capital financings add up to $1.7bn, including a $135m crossover round for HilleVax after spinning out of Takeda in July to advance a norovirus vaccine, Skyhawk’s $133m in fresh funding and Obsidian’s $115m series B round.
- Drug Discovery Tools
- Other Names / Subsidiaries
- UCB S.A.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.